Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.
about
Immune Cells in Cancer Therapy and Drug DeliveryInterleukin-7 and interleukin-15 for cancerRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cellsPIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?Balancing the innate immune system in tumor development.Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cellsInterferon α may be back on track to treat acute myeloid leukemia.Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.mRNA-based dendritic cell vaccines.Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.CD56 in the Immune System: More Than a Marker for Cytotoxicity?Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.CD56 marks human dendritic cell subsets with cytotoxic potential.CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression.Anticancer Mechanisms in Two Murine Bone Marrow-Derived Dendritic Cell Subsets Activated with TLR4 Agonists.Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
P2860
Q26747061-CBA98B62-CCFF-4B31-9191-4C4FF0E9839BQ26830709-23BBF801-CF72-408A-8A7B-E3F1FB5E5242Q27686800-F8C1833B-B610-4908-B685-5045B006BF15Q33758166-CFCF36B0-6F6E-451D-97C9-79566D125EDEQ34011491-D6FDA114-C89C-4DCF-8919-0233BCBA5CF9Q34076409-FAAA4E77-2BAA-4A9A-B2FC-5D9F46C3B908Q34402141-0CD9B930-45A9-4562-9A0D-0ED27F9FC99AQ35236394-9499562C-B571-433B-8B07-B66A2E8EF06DQ35624376-8359824A-17DE-435A-AF40-2DDAD78A688CQ36107961-E4EC401D-F3D0-4B3C-AC53-FB5260254854Q37294760-31C1477B-57DE-4844-BE35-7BD54D002506Q38111770-856358B3-1EB1-4AC2-A828-865688575B6DQ38115438-DEE1B895-03EE-4EE4-8E0A-4DDE63F80D7AQ38246769-B8B4C1F4-2AF2-446C-8C0C-0FC7E33DF7BAQ39014899-5F4C7BA5-0BC1-4ACC-8D5D-1AA7E2E525FAQ39015531-DCA41EE1-103F-4046-BB31-67F1C9C077AFQ40101148-10E72309-36BF-40BC-9C3F-D766014EC2C3Q40733554-144274E8-46F8-43AB-8E1A-00F2195FDFF3Q41343094-264C0402-5F3F-4915-A7DE-950F7CD5818CQ42269630-EF6BC34D-5738-4FA3-8582-CECD6A941AEDQ47677316-675C145B-0206-4A66-A2E6-2C49FC31B701Q50533018-6522D2B6-65B2-4D4B-8D3C-58093E5178ACQ56967396-29928064-4BC3-49EF-861B-555418138DED
P2860
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Interleukin-15-induced CD56
@nl
Interleukin-15-induced CD56(+) ...... direct tumoricidal potential.
@ast
Interleukin-15-induced CD56(+) ...... direct tumoricidal potential.
@en
type
label
Interleukin-15-induced CD56
@nl
Interleukin-15-induced CD56(+) ...... direct tumoricidal potential.
@ast
Interleukin-15-induced CD56(+) ...... direct tumoricidal potential.
@en
prefLabel
Interleukin-15-induced CD56
@nl
Interleukin-15-induced CD56(+) ...... direct tumoricidal potential.
@ast
Interleukin-15-induced CD56(+) ...... direct tumoricidal potential.
@en
P2093
P2860
P50
P1433
P1476
Interleukin-15-induced CD56(+) ...... direct tumoricidal potential.
@en
P2093
I Jolanda M de Vries
Karen Couderé
Phillip D Fromm
Sébastien Anguille
P2860
P304
P356
10.1371/JOURNAL.PONE.0051851
P407
P577
2012-12-28T00:00:00Z